title: Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010.
abstract: Phenotypic and genotypic characterization of 133 isolates of Neisseria meningitidis obtained from meningococcal disease cases in Argentina during 2010 were performed by the National Reference Laboratory as part of a project coordinated by the PAHO within the SIREVA II network. Serogroup, serotype, serosubtype and MLST characterization were performed. Minimum Inhibitory Concentration to penicillin, ampicillin, ceftriaxone, rifampin, chloramphenicol, tetracycline and ciprofloxacin were determined and interpreted according to CLSI guidelines. Almost 49% of isolates were W135, and two serotype:serosubtype combinations, W135:2a:P1.5,2:ST-11 and W135:2a:P1.2:ST-11 accounted for 78% of all W135 isolates. Serogroup B accounted for 42.1% of isolates, and was both phenotypically and genotypically diverse. Serogroup C isolates represented 5.3% of the dataset, and one isolate belonging to the ST-198 complex was non-groupable. Isolates belonged mainly to the ST-11 complex (48%) and to a lesser extent to the ST-865 (18%), ST-32 (9,8%) and the ST-35 complexes (9%). Intermediate resistance to penicillin and ampicillin was detected in 35.4% and 33.1% of isolates respectively. Two W135:2a:P1.5,2:ST-11:ST-11 isolates presented resistance to ciprofloxacin associated with a mutation in the QRDR of gyrA gene Thr91-Ile. These data show serogroup W135 was the first cause of disease in Argentina in 2010, and was strongly associated with the W135:2a:P1.5,2:ST-11 epidemic clone. Serogroup B was the second cause of disease and isolates belonging to this serogroup were phenotypically and genotypically diverse. The presence of isolates with intermediate resistance to penicillin and the presence of fluorquinolone-resistant isolates highlight the necessity and importance of maintaining and strengthening National Surveillance Programs.
authors.affiliation: Clinical Bacteriology Service, Department of Bacteriology, National Institute for Infectious Diseases (ANLIS-INEI), 'Dr Carlos G. Malbrán', Ministry of Health, Buenos Aires, Argentina.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Sorhouet-Pereira
authors.forename: Adriana
authors.initials: A
authors.lastname: Efron
authors.forename: Paula
authors.initials: P
authors.lastname: Gagetti
authors.forename: Diego
authors.initials: D
authors.lastname: Faccone
authors.forename: Mabel
authors.initials: M
authors.lastname: Regueira
authors.forename: Alejandra
authors.initials: A
authors.lastname: Corso
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Gabastou
authors.forename: Ana Belén
authors.initials: AB
authors.lastname: Ibarz-Pavón
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology; D001118:Argentina; D002939:Ciprofloxacin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial / Q000187:drug effects / Q000235:genetics; D005838:Genotype; D006801:Humans; D008585:Meningitis, Meningococcal / Q000382:microbiology*; D008826:Microbial Sensitivity Tests; D009345:Neisseria meningitidis / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D010641:Phenotype
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin